文献速递消化、代谢与肾脏急症中毒与环境急症

预测治疗剂量对乙酰氨基酚肝脏适应的代谢组学标志物

Metabolomic markers predictive of hepatic adaptation to therapeutic dosing of acetaminophen.
PubMed 文献 · Clin Toxicol (Phila) · 2021-05-28
一句话结论治疗剂量对乙酰氨基酚用药前血清尿囊酸和鸟氨酸升高与ALT一过性升高相关,基线ALT和碱性磷酸酶亦为显著预测因素。

本研究为母研究的二次分析,纳入美国科罗拉多州丹佛招募的204名受试者,每日服用对乙酰氨基酚4 g至少16天。按监测期间任一時間点ALT是否超过60单位/L分为ALT升高组(n=25)与无升高组(n=179)。第0、7、16、31天血清行超高效液相色谱质谱分析,结果显示用药前第0天样本中尿囊酸和鸟氨酸在ALT升高组显著升高(p=.032),基线ALT(p=.011)和碱性磷酸酶(p=.006)亦显著;这些代谢物独立于种族、民族、性别或BMI。作者认为尿囊酸和鸟氨酸直接参与氮释放和尿素生成通路,进一步研究谷胱甘肽代谢和尿素循环通路可能有助于理解多种药物的肝脏适应机制。

要点

  • 治疗剂量对乙酰氨基酚每日4 g至少16天,204名受试者中25例出现任一监测点ALT>60单位/L。
  • 用药前第0天血清尿囊酸和鸟氨酸在ALT升高组显著升高(p=.032),独立于种族、民族、性别或BMI。
  • 基线ALT(p=.011)和碱性磷酸酶(p=.006)在ALT升高组亦显著升高。
  • 尿囊酸和鸟氨酸直接参与氮释放和尿素生成通路,提示谷胱甘肽代谢和尿素循环通路可能与肝脏适应相关。

适用人群与场景

  • 美国科罗拉多州丹佛招募的受试者,每日服用对乙酰氨基酚4 g至少16天,来自描述治疗剂量对乙酰氨基酚用药期间ALT水平变化的母研究。

诊断标准与关键阈值

  • 按监测期间任一時間点ALT高于60单位/L分为ALT升高组(n=25),无升高者为无升高组(n=179)。

研究设计与关键结果

  • 研究类型为母研究的二次分析,纳入204名受试者,每日对乙酰氨基酚4 g至少16天,按ALT是否>60单位/L分组。
  • 用药前第0天样本中,尿囊酸和鸟氨酸在ALT升高组显著升高(p=.032)。
  • 基线ALT(p=.011)和碱性磷酸酶(p=.006)在ALT升高组亦显著。
  • 上述代谢物显著性独立于种族、民族、性别或BMI。

证据类型、等级与局限

  • 证据类型:母研究的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Drug induced liver injury (DILI) remains a prominent global issue and acetaminophen (APAP) overdose represents a common cause of hepatic injury and DILI. Transient alanine aminotransferase (ALT) elevations have been documented while adhering to recommended daily dosing. However, no metabolites have been identified in pre-treatment samples predicting which patients will develop these transient increases.

METHODS: This was a secondary analysis of samples collected from a parent study describing the course of ALT levels in subjects receiving therapeutic APAP dosing. Two hundred and four subjects recruited from Denver, Colorado received 4 g APAP/daily for at least 16 days. Subjects were grouped by ALT at any monitored time point above 60 units/L (n = 25) vs. no increase (n = 179). Serum samples from days 0, 7, 16, and 31 were run on ultra-high performance liquid chromatography mass spectrometry. We report the metabolomic results of samples analyzed prior to APAP administration and over time. Significant changes in metabolite and demographic variable expressions were explored using t-tests with false discovery rate correction, chi square, and partial least squares discriminant analyses.

RESULTS: Within pre-treatment day 0 samples, allantoate and ornithine were significantly elevated in subjects of the ALT elevation group (p = .032). Baseline ALT (p = .011) and alkaline phosphatase (p = .006) were also significant. These metabolites were significant independent of race, ethnicity, gender, or BMI.

CONCLUSIONS: Allantoate and ornithine are directly involved in pathways related to nitrogen release and urea production. Further investigation into alterations in the glutathione metabolism and urea cycle pathways may lead to a greater understanding of the mechanisms associated with hepatic adaptation for a variety of pharmaceuticals.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Sonn BJ, Heard KJ, Heard SM, et al. Metabolomic markers predictive of hepatic adaptation to therapeutic dosing of acetaminophen. Clin Toxicol (Phila). 2021. PMID: 34047639. doi:10.1080/15563650.2021.1925686

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。